| 2021 | Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea
| CANCER RESEARCH AND TREATMENT |
| 2021 | Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial | CLINICAL CANCER RESEARCH |
| 2021 | First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
| FUTURE ONCOLOGY |
| 2021 | Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma | JOURNAL OF HEPATOLOGY |
| 2021 | Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis | EUROPEAN JOURNAL OF CANCER |
| 2021 | p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer | BIOCHEMICAL PHARMACOLOGY |
| 2020 | Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells
| Genomics & Informatics |
| 2020 | Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I | MOLECULAR CANCER THERAPEUTICS |
| 2020 | Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies | INTERNATIONAL JOURNAL OF CANCER |
| 2020 | Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study | LANCET ONCOLOGY |
| 2020 | Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial | JAMA ONCOLOGY |
| 2020 | Gene Expression Profiling Identifies Akt as a Target for Radiosensitization in Gastric Cancer Cells
| FRONTIERS IN ONCOLOGY |
| 2020 | S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial | LANCET ONCOLOGY |
| 2020 | Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer
| MOLECULAR THERAPY-ONCOLYTICS |
| 2020 | Waun Ki Hong, MD, D.M.Sc (Hon) (1942-2019): A Mentor Who Left Behind a Legacy for Generations to Come
| YONSEI MEDICAL JOURNAL |
| 2020 | Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer
| CLINICAL CANCER RESEARCH |
| 2020 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2020 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
| GASTRIC CANCER |
| 2020 | Glutathione 주사에 의해 유발된 치명적인 천식발작 1예
| ALLERGY ASTHMA & RESPIRATORY DISEASE |
| 2020 | Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies | JOURNAL OF THORACIC ONCOLOGY |
| 2020 | Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
| CLINICAL CANCER RESEARCH |
| 2020 | Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
| GASTRIC CANCER |
| 2020 | Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial
| JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE |
| 2020 | Changes in taste and food preferences in breast cancer patients receiving chemotherapy: a pilot study | SUPPORTIVE CARE IN CANCER |
| 2020 | Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2019 | Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer | ONCOLOGIST |
| 2019 | Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer | EUROPEAN JOURNAL OF CANCER |
| 2019 | Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer | GASTRIC CANCER |
| 2019 | Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
| Journal for Immunotherapy of Cancer |
| 2019 | Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial | JAMA Network Open |
| 2019 | Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
| CANCER RESEARCH AND TREATMENT |
| 2019 | Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
| Gastric Cancer |
| 2019 | Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients
| Cancer Research and Treatment |
| 2019 | Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma | Oncology |
| 2019 | Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
| Cancer Research and Treatment |
| 2019 | Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients
| Cancer Research and Treatment |
| 2019 | A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors | Clinical Cancer Research |
| 2019 | Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer | RADIOTHERAPY AND ONCOLOGY |
| 2019 | Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design
| FUTURE ONCOLOGY |
| 2019 | Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2019 | Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2019 | Role of probe-based confocal laser endomicroscopy-targeted biopsy in the molecular and histopathological study of gastric cancer | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2019 | S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
| CANCER RESEARCH AND TREATMENT |
| 2018 | Identification of Natural Products as Novel PI3KβInhibitors ThroughPharmacophore-based Virtual Screening | BULLETIN OF THE KOREAN CHEMICAL SOCIETY |
| 2018 | Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials | CLINICAL BREAST CANCER |
| 2018 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial | LANCET |
| 2018 | Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer
| JOURNAL OF CELLULAR AND MOLECULAR MEDICINE |
| 2018 | Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer | ANTICANCER RESEARCH |
| 2018 | Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial | CLINICAL CANCER RESEARCH |
| 2018 | Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. | JOURNAL OF GLOBAL ONCOLOGY |
http://orcid.org/0000-0002-0920-9471
(7404006815)
